Physician profile
Raphael E Strauss
NPI 1306947775
$2,251.00
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $275 · 2021: $639 · 2022: $152.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $341.63 | 2019-2022 | |
| Genzyme Corporation | $309.48 | 2019-2021 | |
| Glaxosmithkline, LLC. | $309.13 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $297.05 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.97 | 2019-2021 | |
| Kaleo, INC. | $175.54 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $118.21 | 2019-2022 | |
| Alk-Abello, INC | $87.67 | 2019-2021 | |
| Phadia US INC. | $72.40 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $72.18 | 2019 | |
| Optinose US, INC. | $61.09 | 2019-2021 | |
| Pfizer INC. | $49.60 | 2019 | |
| Greer Laboratories, INC. | $46.26 | 2019 | |
| Octapharma USA, INC. | $27.40 | 2021 | |
| Genentech USA, INC. | $17.50 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $16.84 | 2020 | |
| Amgen INC. | $15.65 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.58 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.97 | 2021 | |
| Covis Pharma Gmbh | $13.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Strauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.